Details of the Drug Combination

General Information of Drug Combination (ID: DCVSPZF)

Drug Combination Name
Docetaxel Ifosfamide
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs Docetaxel   DMDI269 Ifosfamide   DMCT3I8
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: OVCAR3
Zero Interaction Potency (ZIP) Score: 6.87
Bliss Independence Score: 7.69
Loewe Additivity Score: 13.18
LHighest Single Agent (HSA) Score: 8.53

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Docetaxel
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [2]
Breast carcinoma N.A. Approved [2]
Head and neck cancer 2D42 Approved [2]
Leiomyosarcoma 2B58 Approved [2]
Lung cancer 2C25.0 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Prostate adenocarcinoma N.A. Approved [2]
Prostate cancer 2C82.0 Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Urinary system neoplasm N.A. Approved [2]
Gastric cancer 2B72 Investigative [2]
Docetaxel Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Inhibitor [9]
------------------------------------------------------------------------------------
Docetaxel Interacts with 8 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [10]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [11]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [13]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [14]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [15]
TAP-like protein (ABCB9) DT68UV2 ABCB9_HUMAN Substrate [16]
Multidrug resistance-associated protein 7 (ABCC10) DTPS120 MRP7_HUMAN Substrate [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DTP(s)
Docetaxel Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [18]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [19]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [19]
------------------------------------------------------------------------------------
Docetaxel Interacts with 83 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Response To Substance [20]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Increases ADR [21]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Increases Expression [22]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Response To Substance [20]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [23]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [24]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [25]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [25]
Progesterone receptor (PGR) OT0FZ3QE PRGR_HUMAN Decreases Expression [25]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Decreases Expression [25]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Increases Expression [25]
Dihydropyrimidine dehydrogenase (DPYD) OTWRF2NR DPYD_HUMAN Decreases Activity [6]
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) OTBPCU2O TR10A_HUMAN Increases Expression [26]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [26]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Degradation [27]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [28]
PC4 and SFRS1-interacting protein (PSIP1) OT4YAFUS PSIP1_HUMAN Increases Cleavage [29]
RAF proto-oncogene serine/threonine-protein kinase (RAF1) OT51LSFO RAF1_HUMAN Increases Expression [30]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Increases Secretion [31]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [7]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Phosphorylation [32]
Protein kinase C beta type (PRKCB) OTYQ0656 KPCB_HUMAN Increases Phosphorylation [33]
Keratin, type I cytoskeletal 18 (KRT18) OTVLQFIP K1C18_HUMAN Increases Expression [34]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Increases Activity [35]
Prostate-specific antigen (KLK3) OTFGSBFJ KLK3_HUMAN Decreases Expression [36]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [32]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Decreases Expression [37]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [38]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Increases Expression [39]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3) OTC1UOHP ATF3_HUMAN Decreases Expression [40]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Decreases Expression [40]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Increases Activity [35]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [41]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [30]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [30]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [8]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [40]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Phosphorylation [42]
Caspase-2 (CASP2) OTUDYSPP CASP2_HUMAN Increases Activity [29]
Cyclin-dependent kinase inhibitor 2A (CDKN2A) OTN0ZWAE CDN2A_HUMAN Decreases Expression [43]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Decreases Expression [23]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [44]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [45]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [7]
Focal adhesion kinase 1 (PTK2) OT3Q1JDY FAK1_HUMAN Increases Cleavage [46]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [47]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Increases Expression [27]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [46]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Activity [27]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Decreases Phosphorylation [27]
ELL-associated factor 2 (EAF2) OTSOET5L EAF2_HUMAN Decreases Expression [40]
Small integral membrane protein 14 (SMIM14) OT47IF19 SIM14_HUMAN Decreases Expression [40]
Protein FAM117A (FAM117A) OT2FBGGV F117A_HUMAN Decreases Expression [40]
Delta-like protein 4 (DLL4) OTRA4K2V DLL4_HUMAN Increases Expression [44]
Tumor necrosis factor receptor superfamily member 19 (TNFRSF19) OTTVT4MB TNR19_HUMAN Decreases Expression [40]
Tropomodulin-2 (TMOD2) OTTTUH2W TMOD2_HUMAN Decreases Expression [40]
Flavin-containing monooxygenase 3 (FMO3) OT1G2EV3 FMO3_HUMAN Affects Response To Substance [48]
Kinesin heavy chain isoform 5A (KIF5A) OT3ETTI6 KIF5A_HUMAN Decreases Response To Substance [49]
Proteinase-activated receptor 1 (F2R) OT4WVWBO PAR1_HUMAN Decreases Response To Substance [50]
ATP-binding cassette sub-family G member 1 (ABCG1) OT5BG6MK ABCG1_HUMAN Affects Response To Substance [48]
Regulator of G-protein signaling 17 (RGS17) OT5RVUDS RGS17_HUMAN Increases Response To Substance [51]
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (BUB1B) OT8KME51 BUB1B_HUMAN Affects Response To Substance [52]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Response To Substance [53]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Response To Substance [54]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Decreases Response To Substance [55]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Affects Response To Substance [48]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Increases Response To Substance [20]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Increases Response To Substance [56]
Kinesin-like protein KIFC3 (KIFC3) OTOPD4QO KIFC3_HUMAN Decreases Response To Substance [49]
Regulator of G-protein signaling 10 (RGS10) OTQ8N1QH RGS10_HUMAN Increases Response To Substance [51]
E3 ubiquitin-protein ligase CHFR (CHFR) OTRAD2TT CHFR_HUMAN Decreases Response To Substance [57]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Response To Substance [58]
Cell surface glycoprotein MUC18 (MCAM) OTT8XKGE MUC18_HUMAN Decreases Response To Substance [59]
Kinesin-like protein KIF12 (KIF12) OTTALNDD KIF12_HUMAN Decreases Response To Substance [49]
Nucleophosmin (NPM1) OTTBYYT0 NPM_HUMAN Decreases Response To Substance [60]
Flavin-containing monooxygenase 2 (FMO2) OTUJUL9S FMO2_HUMAN Affects Response To Substance [48]
NADPH--cytochrome P450 reductase (POR) OTVIDOCH NCPR_HUMAN Increases Response To Substance [20]
Kinesin-like protein KIF14 (KIF14) OTXHT4JM KIF14_HUMAN Decreases Response To Substance [61]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1) OTXNGZCG MD2L1_HUMAN Affects Response To Substance [52]
Cellular retinoic acid-binding protein 2 (CRABP2) OTY01V9G RABP2_HUMAN Affects Response To Substance [62]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Affects Response To Substance [63]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Affects Response To Substance [48]
ATP-binding cassette sub-family C member 6 (ABCC6) OTZT0LKT MRP6_HUMAN Affects Response To Substance [48]
------------------------------------------------------------------------------------
⏷ Show the Full List of 83 DOT(s)
Indication(s) of Ifosfamide
Disease Entry ICD 11 Status REF
Adult central nervous system germ cell tumor N.A. Approved [4]
Adult teratoma N.A. Approved [4]
Advanced cancer 2A00-2F9Z Approved [4]
Extragonadal germ cell cancer N.A. Approved [4]
Extragonadal germ cell tumor N.A. Approved [4]
Kidney neoplasm N.A. Approved [4]
Solid tumour/cancer 2A00-2F9Z Approved [5]
Testicular germ cell tumor N.A. Approved [4]
Extragonadal nonseminomatous germ cell tumor N.A. Investigative [4]
Extragonadal seminoma N.A. Investigative [4]
Neuroblastoma 2D11.2 Investigative [4]
Retinoblastoma 2D02.2 Investigative [4]
Ifosfamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [65]
------------------------------------------------------------------------------------
Ifosfamide Interacts with 10 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [66]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Metabolism [67]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [68]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [69]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Metabolism [70]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [68]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [71]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Metabolism [72]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [70]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Metabolism [66]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DME(s)
Ifosfamide Interacts with 214 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Increases Activity [73]
Cytochrome P450 2C18 (CYP2C18) OTY687L9 CP2CI_HUMAN Increases Activity [73]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Ethylation [74]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Decreases Ethylation [74]
Cytochrome P450 2A6 (CYP2A6) OT52TWG3 CP2A6_HUMAN Affects Hydroxylation [67]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Increases Response To Substance [75]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Increases Response To Substance [75]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Increases Response To Substance [76]
Beta-2-microglobulin (B2M) OTDWN6NX B2MG_HUMAN Increases Expression [77]
Alpha-2A adrenergic receptor (ADRA2A) OTZFGOTP ADA2A_HUMAN Increases ADR [78]
Interleukin-19 (IL19) OT9VGDIP IL19_HUMAN Increases Secretion [79]
Solute carrier family 12 member 8 (SLC12A8) OTHJP5FU S12A8_HUMAN Decreases Expression [64]
Toll-like receptor 4 (TLR4) OTP7ML3S TLR4_HUMAN Increases Expression [64]
Agrin (AGRN) OTWJENAZ AGRIN_HUMAN Increases Expression [64]
Podocalyxin (PODXL) OTPNQXF3 PODXL_HUMAN Decreases Expression [64]
Class E basic helix-loop-helix protein 40 (BHLHE40) OTITX14U BHE40_HUMAN Increases Expression [64]
TRAF-type zinc finger domain-containing protein 1 (TRAFD1) OT7AU2R3 TRAD1_HUMAN Increases Expression [64]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [64]
Rho guanine nucleotide exchange factor 10 (ARHGEF10) OTHJ1Y4I ARHGA_HUMAN Affects Expression [64]
Protein phosphatase 1D (PPM1D) OT8NLZ9D PPM1D_HUMAN Decreases Expression [64]
Apoptosis regulatory protein Siva (SIVA1) OTDT0XZK SIVA_HUMAN Increases Expression [64]
Transcription factor MafG (MAFG) OTBQFUZH MAFG_HUMAN Increases Expression [64]
D-3-phosphoglycerate dehydrogenase (PHGDH) OT1LMRTG SERA_HUMAN Increases Expression [64]
E3 ubiquitin-protein ligase SIAH2 (SIAH2) OTKED2XN SIAH2_HUMAN Increases Expression [64]
Protein regulator of cytokinesis 1 (PRC1) OTHD0XS0 PRC1_HUMAN Increases Expression [64]
TP53-regulated inhibitor of apoptosis 1 (TRIAP1) OTEAUJXN TRIA1_HUMAN Increases Expression [64]
5'-AMP-activated protein kinase subunit beta-2 (PRKAB2) OTLVN68B AAKB2_HUMAN Affects Expression [64]
Mitochondrial carnitine/acylcarnitine carrier protein (SLC25A20) OT6CLFXB MCAT_HUMAN Increases Expression [64]
NUAK family SNF1-like kinase 1 (NUAK1) OTLLHJJQ NUAK1_HUMAN Decreases Expression [64]
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A (PDE8A) OT4RF9Z4 PDE8A_HUMAN Decreases Expression [64]
Mitochondrial import inner membrane translocase subunit Tim17-B (TIMM17B) OTSQGLSB TI17B_HUMAN Decreases Expression [64]
PR domain zinc finger protein 1 (PRDM1) OTQLSVBS PRDM1_HUMAN Decreases Expression [64]
E3 ubiquitin-protein ligase listerin (LTN1) OTIW2HTX LTN1_HUMAN Decreases Expression [64]
Tumor necrosis factor alpha-induced protein 8 (TNFAIP8) OT1G9297 TFIP8_HUMAN Increases Expression [64]
Tetraspanin-12 (TSPAN12) OTF9I3CX TSN12_HUMAN Decreases Expression [64]
G1/S-specific cyclin-E2 (CCNE2) OTBBUKQQ CCNE2_HUMAN Increases Expression [64]
Glutathione reductase, mitochondrial (GSR) OTM2TUYM GSHR_HUMAN Increases Expression [64]
Metallothionein-2 (MT2A) OTHOACHD MT2_HUMAN Increases Expression [64]
Fructose-bisphosphate aldolase A (ALDOA) OTWRFTIB ALDOA_HUMAN Increases Expression [64]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Affects Activity [64]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Expression [64]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Increases Expression [64]
Fatty acid-binding protein, heart (FABP3) OT562DA1 FABPH_HUMAN Decreases Expression [64]
Transcription factor AP-2-alpha (TFAP2A) OTMYT3NK AP2A_HUMAN Decreases Expression [64]
Integrin beta-1 (ITGB1) OT6G1IAR ITB1_HUMAN Affects Expression [64]
Glycogen phosphorylase, liver form (PYGL) OTS1YFGR PYGL_HUMAN Decreases Expression [64]
Amino acid transporter heavy chain SLC3A2 (SLC3A2) OTBR33M9 4F2_HUMAN Increases Expression [64]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Increases Expression [64]
Keratin, type I cytoskeletal 19 (KRT19) OTDGDQ75 K1C19_HUMAN Increases Expression [64]
Gamma-enolase (ENO2) OTRODL0T ENOG_HUMAN Increases Expression [64]
Heat shock 70 kDa protein 1A (HSPA1A) OTKGIE76 HS71A_HUMAN Increases Expression [64]
RNA-binding protein RO60 (RO60) OTLGM5A8 RO60_HUMAN Decreases Expression [64]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1) OTA675TJ GTR1_HUMAN Increases Expression [64]
DNA topoisomerase 1 (TOP1) OT51O0CF TOP1_HUMAN Increases Expression [64]
Cation-independent mannose-6-phosphate receptor (IGF2R) OTDXPQVX MPRI_HUMAN Increases Expression [64]
Prolyl 4-hydroxylase subunit alpha-1 (P4HA1) OTV04QE5 P4HA1_HUMAN Decreases Expression [64]
Fos-related antigen 1 (FOSL1) OT9YTYMB FOSL1_HUMAN Increases Expression [64]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Decreases Expression [64]
Protein SON (SON) OT9VWV18 SON_HUMAN Decreases Expression [64]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Affects Activity [64]
Keratin, type I cytoskeletal 15 (KRT15) OTS6WLF7 K1C15_HUMAN Increases Expression [64]
Ephrin-A1 (EFNA1) OTU2NUA2 EFNA1_HUMAN Decreases Expression [64]
Iduronate 2-sulfatase (IDS) OTZO94EO IDS_HUMAN Decreases Expression [64]
Ferrochelatase, mitochondrial (FECH) OTDWEI6C HEMH_HUMAN Decreases Expression [64]
Diacylglycerol kinase alpha (DGKA) OTTBVNEZ DGKA_HUMAN Increases Expression [64]
Thromboxane-A synthase (TBXAS1) OTAXZJJ4 THAS_HUMAN Increases Expression [64]
Bromodomain-containing protein 2 (BRD2) OTQP2MVJ BRD2_HUMAN Decreases Expression [64]
DnaJ homolog subfamily B member 2 (DNAJB2) OTZHPV5M DNJB2_HUMAN Increases Expression [64]
Neuropeptide Y receptor type 1 (NPY1R) OT5DA9DY NPY1R_HUMAN Increases Expression [64]
Threonine--tRNA ligase 1, cytoplasmic (TARS1) OT0PWST5 SYTC_HUMAN Decreases Expression [64]
Adenylate kinase 4, mitochondrial (AK4) OTA0T02Q KAD4_HUMAN Increases Expression [64]
ETS domain-containing protein Elk-4 (ELK4) OTVSSEOE ELK4_HUMAN Decreases Expression [64]
Tyrosine-protein kinase receptor UFO (AXL) OTKA2SUX UFO_HUMAN Increases Expression [64]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Increases Expression [64]
Pyrroline-5-carboxylate reductase 1, mitochondrial (PYCR1) OTQHB52T P5CR1_HUMAN Increases Expression [64]
Cystathionine gamma-lyase (CTH) OTC90LA0 CGL_HUMAN Affects Expression [64]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1) OTB06ESI ACSL1_HUMAN Decreases Expression [64]
Thrombospondin-2 (THBS2) OTXET551 TSP2_HUMAN Decreases Expression [64]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [64]
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Affects Activity [64]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Affects Activity [64]
Transaldolase (TALDO1) OTDKV2S2 TALDO_HUMAN Increases Expression [64]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [64]
Glycine--tRNA ligase (GARS1) OT5B6R9Y GARS_HUMAN Increases Expression [64]
Isoleucine--tRNA ligase, cytoplasmic (IARS1) OT9WXH5N SYIC_HUMAN Increases Expression [64]
Tumor necrosis factor ligand superfamily member 9 (TNFSF9) OTV9L89D TNFL9_HUMAN Increases Expression [64]
Eukaryotic translation initiation factor 1 (EIF1) OTB4GZ0V EIF1_HUMAN Increases Expression [64]
ATP-binding cassette sub-family G member 1 (ABCG1) OT5BG6MK ABCG1_HUMAN Decreases Expression [64]
Retinaldehyde dehydrogenase 3 (ALDH1A3) OT1C9NKQ AL1A3_HUMAN Increases Expression [64]
Sodium- and chloride-dependent glycine transporter 1 (SLC6A9) OTHRUON2 SC6A9_HUMAN Decreases Expression [64]
NADP-dependent malic enzyme (ME1) OTSVEUQE MAOX_HUMAN Decreases Expression [64]
Glutamate--cysteine ligase catalytic subunit (GCLC) OTESDI4D GSH1_HUMAN Decreases Expression [64]
Glutamate--cysteine ligase regulatory subunit (GCLM) OT6CP234 GSH0_HUMAN Increases Expression [64]
Cysteine--tRNA ligase, cytoplasmic (CARS1) OTOUZF6O SYCC_HUMAN Decreases Expression [64]
Serine--tRNA ligase, cytoplasmic (SARS1) OTFKXQ1O SYSC_HUMAN Increases Expression [64]
Max-interacting protein 1 (MXI1) OTUQ9E0D MXI1_HUMAN Decreases Expression [64]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Increases Expression [64]
Dipeptidyl peptidase 1 (CTSC) OT79WJZZ CATC_HUMAN Increases Expression [64]
Ataxin-1 (ATXN1) OTQF0HNR ATX1_HUMAN Decreases Expression [64]
Branched-chain-amino-acid aminotransferase, cytosolic (BCAT1) OTYHXLWZ BCAT1_HUMAN Decreases Expression [64]
Homeobox protein DLX-1 (DLX1) OT7BH057 DLX1_HUMAN Decreases Expression [64]
Protein BTG2 (BTG2) OTZF6K1H BTG2_HUMAN Increases Expression [64]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Affects Expression [64]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [64]
Large neutral amino acids transporter small subunit 1 (SLC7A5) OT2WPVXD LAT1_HUMAN Increases Expression [64]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [64]
Transmembrane protein 94 (TMEM94) OTT4ZSUA TMM94_HUMAN Decreases Expression [64]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) OT4SO7J4 BNIP3_HUMAN Decreases Expression [64]
Zinc finger protein Rlf (RLF) OTCSPZVK RLF_HUMAN Increases Expression [64]
Peptidyl-prolyl cis-trans isomerase G (PPIG) OTZ8BTTM PPIG_HUMAN Decreases Expression [64]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Increases Expression [64]
Ras-related protein Rab-31 (RAB31) OTMLXQZ0 RAB31_HUMAN Increases Expression [64]
Kelch-like ECH-associated protein 1 (KEAP1) OTFHOD0C KEAP1_HUMAN Increases Expression [64]
Src substrate cortactin (CTTN) OTJRG4ES SRC8_HUMAN Increases Expression [64]
Enhancer of filamentation 1 (NEDD9) OTGCFN4M CASL_HUMAN Decreases Expression [64]
Protein disulfide-isomerase A5 (PDIA5) OT76ZSX5 PDIA5_HUMAN Increases Expression [64]
Condensin complex subunit 1 (NCAPD2) OT8VGE2O CND1_HUMAN Increases Expression [64]
Probable E3 ubiquitin-protein ligase HERC3 (HERC3) OTWMKYD9 HERC3_HUMAN Decreases Expression [64]
kinase isozyme 1, mitochondrial (PDK1) OTMABK9Z PDK1_HUMAN Decreases Expression [64]
Neutral amino acid transporter B(0) (SLC1A5) OTE2H26Q AAAT_HUMAN Increases Expression [64]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Affects Activity [64]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Decreases Expression [64]
Neuronal regeneration-related protein (NREP) OT2AZPKK NREP_HUMAN Affects Expression [64]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Affects Activity [64]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Expression [64]
Laminin subunit alpha-3 (LAMA3) OTFME7HT LAMA3_HUMAN Increases Expression [64]
Atos homolog protein A (ATOSA) OTWFM5G0 ATOSA_HUMAN Decreases Expression [64]
Glycerol-3-phosphate acyltransferase 3 (GPAT3) OTJUGPK0 GPAT3_HUMAN Increases Expression [64]
Quinone oxidoreductase PIG3 (TP53I3) OTSCM68G QORX_HUMAN Increases Expression [64]
RRP12-like protein (RRP12) OTQQAEH4 RRP12_HUMAN Increases Expression [64]
ALS2 C-terminal-like protein (ALS2CL) OT8RY7TZ AL2CL_HUMAN Affects Expression [64]
Dynamin-binding protein (DNMBP) OTMHH14H DNMBP_HUMAN Increases Expression [64]
Ribosomal protein eS27-like (RPS27L) OTZWHU0N RS27L_HUMAN Increases Expression [64]
Arginine/serine-rich coiled-coil protein 2 (RSRC2) OTLE0KQM RSRC2_HUMAN Decreases Expression [64]
Mitochondrial enolase superfamily member 1 (ENOSF1) OT65D3ZK ENOF1_HUMAN Decreases Expression [64]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B) OTE8GBUR RIR2B_HUMAN Decreases Expression [64]
Protein LYRIC (MTDH) OTGH7N4C LYRIC_HUMAN Decreases Expression [64]
Liprin-beta-1 (PPFIBP1) OTRA2S7B LIPB1_HUMAN Increases Expression [64]
Dynein axonemal intermediate chain 3 (DNAI3) OTG1A0QP DNAI3_HUMAN Decreases Expression [64]
Extracellular sulfatase Sulf-2 (SULF2) OTIXMUVL SULF2_HUMAN Decreases Expression [64]
Protein O-mannosyl-transferase TMTC2 (TMTC2) OTY1QWYU TMTC2_HUMAN Decreases Expression [64]
Ninein (NIN) OTVH3M4Z NIN_HUMAN Decreases Expression [64]
Ceramide synthase 5 (CERS5) OT5A2DNI CERS5_HUMAN Increases Expression [64]
Uncharacterized protein C8orf58 (C8ORF58) OTHW01L0 CH058_HUMAN Increases Expression [64]
F-box only protein 22 (FBXO22) OTEJ5MO0 FBX22_HUMAN Increases Expression [64]
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4) OTQK3M9X ABHD4_HUMAN Increases Expression [64]
F-box only protein 30 (FBXO30) OTD1P6LA FBX30_HUMAN Decreases Expression [64]
Pantothenate kinase 1 (PANK1) OT2CZVRT PANK1_HUMAN Decreases Expression [64]
SH3 domain and tetratricopeptide repeat-containing protein 1 (SH3TC1) OT0HYZIU S3TC1_HUMAN Decreases Expression [64]
Uncharacterized protein C4orf3 (C4ORF3) OT6TFN1O CD003_HUMAN Decreases Expression [64]
Paraspeckle component 1 (PSPC1) OTYS6WQ8 PSPC1_HUMAN Decreases Expression [64]
Histone acetyltransferase KAT6B (KAT6B) OTMUDTAH KAT6B_HUMAN Decreases Expression [64]
E3 ubiquitin-protein ligase rififylin (RFFL) OT85MGDH RFFL_HUMAN Increases Expression [64]
Probable ATP-dependent RNA helicase DDX17 (DDX17) OTXRMMBP DDX17_HUMAN Decreases Expression [64]
GTP-binding protein Rit1 (RIT1) OTVNOGOH RIT1_HUMAN Increases Expression [64]
KICSTOR complex protein ITFG2 (ITFG2) OT0NLZ8I ITFG2_HUMAN Decreases Expression [64]
Protein TMEPAI (PMEPA1) OTY8Z9UF PMEPA_HUMAN Increases Expression [64]
Protein FAM162A (FAM162A) OT882DND F162A_HUMAN Decreases Expression [64]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1) OT2363Z9 T53I1_HUMAN Increases Expression [64]
SPRY domain-containing SOCS box protein 1 (SPSB1) OTGY26U4 SPSB1_HUMAN Increases Expression [64]
Carboxymethylenebutenolidase homolog (CMBL) OT8H3S3G CMBL_HUMAN Increases Expression [64]
Aurora kinase B (AURKB) OTIY4VHU AURKB_HUMAN Increases Expression [64]
Protein FAM89A (FAM89A) OTNASAXT FA89A_HUMAN Increases Expression [64]
ERO1-like protein alpha (ERO1A) OTVKOQWM ERO1A_HUMAN Increases Expression [64]
Protein FAM210B, mitochondrial (FAM210B) OT2QHEQ6 F210B_HUMAN Decreases Expression [64]
E1A-binding protein p400 (EP400) OTVQ75NX EP400_HUMAN Decreases Expression [64]
Calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) OT9C3KFI KKCC2_HUMAN Increases Expression [64]
ETS-related transcription factor Elf-4 (ELF4) OT167PR5 ELF4_HUMAN Increases Expression [64]
Eukaryotic translation initiation factor 3 subunit C (EIF3C) OTR8RF9X EIF3C_HUMAN Decreases Expression [64]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [64]
Cancer-related nucleoside-triphosphatase (NTPCR) OTTRT6Z9 NTPCR_HUMAN Increases Expression [64]
G-protein coupled receptor 87 (GPR87) OTQX45UM GPR87_HUMAN Decreases Expression [64]
Sulfiredoxin-1 (SRXN1) OTYDBO4L SRXN1_HUMAN Increases Expression [64]
G protein-coupled receptor 88 (GPR88) OTGAT70V GPR88_HUMAN Increases Expression [64]
Coiled-coil domain-containing protein 90B, mitochondrial (CCDC90B) OTFFWB0C CC90B_HUMAN Decreases Expression [64]
Polyprenol reductase (SRD5A3) OT9IJLX7 PORED_HUMAN Decreases Expression [64]
E3 ubiquitin ligase RNF121 (RNF121) OTA0YMLW RN121_HUMAN Decreases Expression [64]
Ankyrin repeat family A protein 2 (ANKRA2) OTLSLV5A ANRA2_HUMAN Decreases Expression [64]
p53-induced death domain-containing protein 1 (PIDD1) OTWFM930 PIDD1_HUMAN Decreases Expression [64]
ATP-binding cassette sub-family B member 6 (ABCB6) OTPGZFES ABCB6_HUMAN Increases Expression [64]
ABC-type oligopeptide transporter ABCB9 (ABCB9) OTSOBOL5 ABCB9_HUMAN Increases Expression [64]
Fructose-2,6-bisphosphatase TIGAR (TIGAR) OTR7NMRJ TIGAR_HUMAN Increases Expression [64]
Dual specificity protein phosphatase 22 (DUSP22) OTEZ3U85 DUS22_HUMAN Increases Expression [64]
PAK4-inhibitor INKA2 (INKA2) OT9RA64U INKA2_HUMAN Increases Expression [64]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Increases Expression [64]
LIM and cysteine-rich domains protein 1 (LMCD1) OT3AWE8O LMCD1_HUMAN Decreases Expression [64]
Signal-induced proliferation-associated 1-like protein 2 (SIPA1L2) OT8NJE5D SI1L2_HUMAN Decreases Expression [64]
Dolichol-phosphate mannosyltransferase subunit 3 (DPM3) OTSB4XO0 DPM3_HUMAN Increases Expression [64]
DnaJ homolog subfamily B member 9 (DNAJB9) OT38EQT6 DNJB9_HUMAN Increases Expression [64]
Mitochondrial fission process protein 1 (MTFP1) OT3L6F7U MTFP1_HUMAN Increases Expression [64]
SERTA domain-containing protein 1 (SERTAD1) OTBHKZQP SRTD1_HUMAN Increases Expression [64]
Oxidative stress-induced growth inhibitor 1 (OSGIN1) OT9KIVZW OSGI1_HUMAN Decreases Expression [64]
Heme transporter FLVCR2 (FLVCR2) OTAM94ID FLVC2_HUMAN Decreases Expression [64]
Exocyst complex component 7 (EXOC7) OT4YA137 EXOC7_HUMAN Increases Expression [64]
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1) OT1OG4QZ AAKB1_HUMAN Affects Expression [64]
Lysine-specific demethylase 3A (KDM3A) OTZYJ8VN KDM3A_HUMAN Decreases Expression [64]
RNA polymerase II subunit A C-terminal domain phosphatase (CTDP1) OTHHFW17 CTDP1_HUMAN Decreases Expression [64]
Pleckstrin homology-like domain family A member 3 (PHLDA3) OTXFUDO2 PHLA3_HUMAN Increases Expression [64]
Insulin-induced gene 2 protein (INSIG2) OTX4VY51 INSI2_HUMAN Increases Expression [64]
Phosphoserine aminotransferase (PSAT1) OTVV1YV9 SERC_HUMAN Increases Expression [64]
Sestrin-1 (SESN1) OTSFDZWL SESN1_HUMAN Increases Expression [64]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [28]
HLA class I histocompatibility antigen, B alpha chain (HLA-B) OTNXFWY2 HLAB_HUMAN Affects Expression [80]
Osteocalcin (BGLAP) OTK1YLWQ OSTCN_HUMAN Decreases Expression [81]
HLA class I histocompatibility antigen, A alpha chain (HLA-A) OTAH14LU HLAA_HUMAN Affects Expression [80]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [28]
HLA class I histocompatibility antigen, alpha chain G (HLA-G) OTMLK1KN HLAG_HUMAN Affects Expression [80]
Glutathione peroxidase 3 (GPX3) OT6PK94R GPX3_HUMAN Decreases Activity [82]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Affects Expression [80]
Elastin (ELN) OTFSO7PG ELN_HUMAN Increases ADR [78]
S-adenosylmethionine decarboxylase proenzyme (AMD1) OTKAGZY3 DCAM_HUMAN Increases ADR [78]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Increases Response To Substance [83]
Ornithine decarboxylase (ODC1) OTNDAGRR DCOR_HUMAN Increases ADR [78]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Increases Response To Substance [75]
------------------------------------------------------------------------------------
⏷ Show the Full List of 214 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCDN1H2 HCT116 Investigative [1]
Chronic myelogenous leukemia DC8A0UW K-562 Investigative [1]
High grade ovarian serous adenocarcinoma DC0IA3B OVCAR-8 Investigative [1]
Large cell lung carcinoma DCGNNY3 NCI-H460 Investigative [1]
Mixed endometrioid and clear cell carcinoma DCJSI7X IGROV1 Investigative [1]
Renal cell carcinoma DCI9AOA SN12C Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Docetaxel FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6809).
4 Ifosfamide FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7201).
6 Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer. 2006 Aug 15;119(4):783-91.
7 Induction of tubulin by docetaxel is associated with p53 status in human non small cell lung cancer cell lines. Int J Cancer. 2006 Jan 15;118(2):317-25. doi: 10.1002/ijc.21372.
8 Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer. 2005 Jun 20;115(3):484-92. doi: 10.1002/ijc.20878.
9 Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
10 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
11 Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
12 Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010 Aug 10;103(4):560-6.
13 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
14 FDA Drug Development and Drug Interactions
15 Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9.
16 RNA-sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel. Mol Biosyst. 2017 Sep 26;13(10):2125-2134.
17 Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
18 Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol. 2005 Feb 20;23(6):1061-9.
19 Drug Interactions Flockhart Table
20 Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
21 Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008 May;99(5):967-72.
22 Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer. 2004 Sep 10;111(4):484-93. doi: 10.1002/ijc.20230.
23 Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
24 Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
25 Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers. Clin Cancer Res. 2004 Dec 15;10(24):8163-9.
26 Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 2001 Jan 15;61(2):759-63.
27 Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res. 2007 Feb 15;13(4):1308-14. doi: 10.1158/1078-0432.CCR-06-2216.
28 PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010 Sep;66(4):765-71. doi: 10.1007/s00280-009-1221-4. Epub 2009 Dec 30.
29 Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol Cancer. 2009 Aug 28;8:68. doi: 10.1186/1476-4598-8-68.
30 Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells. Front Biosci. 2005 Sep 1;10:2566-75. doi: 10.2741/1720.
31 Kaempferol and quercetin stimulate granulocyte-macrophage colony-stimulating factor secretion in human prostate cancer cells. Mol Cell Endocrinol. 2008 Jun 11;287(1-2):57-64. doi: 10.1016/j.mce.2008.01.015. Epub 2008 Feb 3.
32 All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene. 2004 Jan 15;23(2):426-33. doi: 10.1038/sj.onc.1207040.
33 Docetaxel Facilitates Endothelial Dysfunction through Oxidative Stress via Modulation of Protein Kinase C Beta: The Protective Effects of Sotrastaurin. Toxicol Sci. 2015 May;145(1):59-67. doi: 10.1093/toxsci/kfv017. Epub 2015 Jan 28.
34 Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer. 2006 Jun 5;94(11):1592-8. doi: 10.1038/sj.bjc.6603129.
35 The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 2004 Jan;3(1):59-70.
36 Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010 Oct 15;70(20):7992-8002. doi: 10.1158/0008-5472.CAN-10-0585. Epub 2010 Aug 31.
37 Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer. Biochem Pharmacol. 2011 Nov 1;82(9):1100-9. doi: 10.1016/j.bcp.2011.07.078. Epub 2011 Jul 23.
38 Replication-dependent -H2AX formation is involved in docetaxel-induced apoptosis in NSCLC A549 cells. Oncol Rep. 2010 Nov;24(5):1297-305. doi: 10.3892/or_00000986.
39 Docetaxel induced cardiotoxicity. Heart. 2001 Aug;86(2):219. doi: 10.1136/heart.86.2.219.
40 Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
41 [The mechanism of docetaxel-induced apoptosis in human lung cancer cells]. Zhonghua Zhong Liu Za Zhi. 2000 May;22(3):208-11.
42 Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. J Nutr Biochem. 2015 Apr;26(4):408-15. doi: 10.1016/j.jnutbio.2014.11.017. Epub 2015 Jan 15.
43 Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
44 Role of delta-like ligand-4 in chemoresistance against docetaxel in MCF-7 cells. Hum Exp Toxicol. 2017 Apr;36(4):328-338. doi: 10.1177/0960327116650006. Epub 2016 Jun 22.
45 Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance. Chem Biol Interact. 2021 May 1;340:109448. doi: 10.1016/j.cbi.2021.109448. Epub 2021 Mar 26.
46 Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8829-36. doi: 10.1158/1078-0432.CCR-05-1728.
47 Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy. J Oral Pathol Med. 2005 Feb;34(2):93-9. doi: 10.1111/j.1600-0714.2004.00257.x.
48 Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries. OMICS. 2013 Jul;17(7):353-67. doi: 10.1089/omi.2013.0019. Epub 2013 Jun 11.
49 Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Res Treat. 2012 Feb;131(3):849-58. doi: 10.1007/s10549-011-1500-8. Epub 2011 Apr 9.
50 PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem. 2005 Oct 15;96(3):641-52. doi: 10.1002/jcb.20533.
51 Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells. Mol Cancer. 2010 Nov 2;9:289. doi: 10.1186/1476-4598-9-289.
52 Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol (R Coll Radiol). 2008 Oct;20(8):639-46. doi: 10.1016/j.clon.2008.06.010. Epub 2008 Aug 8.
53 EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). Arch Toxicol. 2015 Apr;89(4):591-605. doi: 10.1007/s00204-014-1275-x. Epub 2014 Jun 3.
54 [Antisense RNA targeting survivin enhances the chemosensitivity of LOVO/Adr cells to taxotere]. Zhonghua Wei Chang Wai Ke Za Zhi. 2005 Sep;8(5):455-8.
55 Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma. Antioxid Redox Signal. 2014 May 20;20(15):2326-46. doi: 10.1089/ars.2013.5295. Epub 2013 Nov 14.
56 HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat. 2004 Aug;86(3):197-206. doi: 10.1023/B:BREA.0000036783.88387.47.
57 Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int J Oncol. 2007 Oct;31(4):713-20.
58 Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Res. 2005 May-Jun;25(3c):2367-79.
59 CD146 expression in human breast cancer cell lines induces phenotypic and functional changes observed in Epithelial to Mesenchymal Transition. PLoS One. 2012;7(8):e43752. doi: 10.1371/journal.pone.0043752. Epub 2012 Aug 30.
60 Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
61 KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer. Neoplasia. 2014 Mar;16(3):247-56, 256.e2. doi: 10.1016/j.neo.2014.03.008.
62 The prognostic gene CRABP2 affects drug sensitivity by regulating docetaxel-induced apoptosis in breast invasive carcinoma: A pan-cancer analysis. Chem Biol Interact. 2023 Mar 1;373:110372. doi: 10.1016/j.cbi.2023.110372. Epub 2023 Feb 2.
63 Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther. 2008 Jan;7(1):19-26. doi: 10.1158/1535-7163.MCT-07-0557. Epub 2008 Jan 9.
64 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
65 Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
66 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
67 Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92.
68 Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
69 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
70 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
71 CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
72 A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem. 2003 Apr 18;278(16):14146-52.
73 Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
74 Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos. 2005 Jul;33(7):1074-81. doi: 10.1124/dmd.104.002279. Epub 2005 Apr 8.
75 Advantages of human hepatocyte-derived transformants expressing a series of human cytochrome p450 isoforms for genotoxicity examination. Toxicol Sci. 2010 Aug;116(2):488-97. doi: 10.1093/toxsci/kfq154. Epub 2010 May 27.
76 Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res. 1998 Oct 1;58(19):4391-401.
77 A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer. 1995 Dec 15;76(12):2557-64. doi: 10.1002/1097-0142(19951215)76:12<2557::aid-cncr2820761223>3.0.co;2-9.
78 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
79 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
80 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
81 Abnormalities in serum osteocalcin values in children receiving chemotherapy including ifosfamide. In Vivo. 1992 Mar-Apr;6(2):219-21.
82 Plasma glutathione peroxidase and its relationship to renal proximal tubule function. Mol Genet Metab. 1998 Nov;65(3):238-45. doi: 10.1006/mgme.1998.2760.
83 Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children. J Pediatr Hematol Oncol. 2005 Nov;27(11):582-9. doi: 10.1097/01.mph.0000187429.52616.8a.